SCHEMBL1747412

SCHEMBL1747412

CCOC(=O)C(C)(C)Oc1ccc(OCc2cccc(-c3ccccc3)c2)cc1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FFAR1 O14842 10/20 0.55
FFAR4 Q5NUL3 2/20 0.55
AKR1B1 P15121 1/20 0.55
PPARA Q07869 3/20 0.52
ABCB11 O95342 1/20 0.52
CYP1A2 P05177 1/20 0.52
CYP3A4 P08684 1/20 0.52
TSHR P16473 1/20 0.52
HTR2A P28223 1/20 0.52
PMP22 Q01453 1/20 0.52
NR4A2 P43354 1/20 0.51
PPARG P37231 4/20 0.51
PPARD Q03181 2/20 0.50
MMP1 P03956 1/20 0.49
MMP2 P08253 1/20 0.49
MMP9 P14780 1/20 0.49
MMP14 P50281 1/20 0.49
ADAM17 P78536 1/20 0.49
MRGPRX4 Q96LA9 2/20 0.49
TP53 P04637 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4428685 0.89 PPARG (0.61) PPARAABCB11CYP1A2CYP3A4TSHR
SCHEMBL1746488 0.87 PPARG (0.61) FFAR1FFAR4PPARAABCB11CYP1A2
SCHEMBL1744611 0.87 PPARG (0.66) FFAR1FFAR4AKR1B1PPARANR4A2
SCHEMBL14584455 0.80 PPARG (0.61) PPARAABCB11CYP1A2CYP3A4TSHR
SCHEMBL6699615 0.80 PPARG (0.53) FFAR1PPARAABCB11CYP1A2CYP3A4
SCHEMBL5660177 0.79 PPARG (0.62) FFAR1PPARAABCB11CYP1A2CYP3A4
SCHEMBL2824491 0.78 PPARA (0.71) PPARAABCB11CYP1A2CYP3A4TSHR
SCHEMBL22924936 0.78 PPARA (0.70) FFAR1PPARAPPARGPPARDTP53
SCHEMBL5660644 0.77 OPRK1 (0.60) PPARANR4A2PPARGPPARDMRGPRX4
SCHEMBL21991804 0.77 PPARA (0.79) FFAR1PPARAABCB11CYP1A2CYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1559422-B1 RECEPTOR FUNCTION CONTROLLING AGENT TAKEDA PHARMACEUTICAL (JP) 2014-04-30 EP disclosed
EP-2385032-A1 GPR40 Receptor function regulator Takeda Pharmaceutical Company Limited (JP) 2011-11-09 EP disclosed
US-7960369-B2 Receptor function regulator TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2011-06-14 US disclosed
US-20090012093-A1 Receptor Function Regulator TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2009-01-08 US disclosed
EP-1559422-A1 RECEPTOR FUNCTION CONTROLLING AGENT Takeda Pharmaceutical Company Limited (JP) 2005-08-03 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090012093-A1 Receptor Function Regulator GPR119, GIPR, INSR FFAR1 33/4885FFAR4 44/4885AKR1B1 1186/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.